{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000326","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.865310+00:00","generated_at":"2026-06-19T04:09:33.036213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Charles River Q4 revenue $1.10B (+21.5% YoY); DOJ subpoena on NHP supply; 2023 guidance below expectations","bullets":["Q4 GAAP EPS $3.65, non-GAAP EPS $2.98; full-year GAAP EPS $9.48, non-GAAP EPS $11.12.","Q4 organic revenue growth 18.8% led by DSA segment (+26.5% organic).","Received DOJ subpoena on Cambodian NHP supply chain; voluntarily suspended shipments from Cambodia.","2023 guidance: reported revenue growth 1.5%-4.5%, organic 4.5%-7.5%; GAAP EPS $7.40-$8.60, non-GAAP $9.70-$10.90.","NHP supply constraints expected to reduce 2023 revenue growth by 200-400 bps; higher tax and interest to pressure EPS."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000326","json":"https://secwatch.observer/filing/0001157523-23-000326.json","markdown":"https://secwatch.observer/filing/0001157523-23-000326.md","text":"https://secwatch.observer/filing/0001157523-23-000326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323000326/0001157523-23-000326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323000326/a53335402.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T04:09:33.036213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa5ad82f51a3fa374e8594eb7b642e44277261da","claim":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported Fourth Quarter 2022 results: revenue $1.10 Billion, net income $187.4 million, EPS $3.65.","evidence_excerpt":"EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance – Fourth-Quarter Revenue of $1.10 Billion and Full-Year Revenue of $3.98 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.65 and Non-GAAP Earnings per Share of $2.98 – – Full-Year GAAP Earnings per Share of $9.48","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323000326/0001157523-23-000326-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2022"},{"label":"Revenue","value":"$1.10 Billion"},{"label":"Net income","value":"$187.4 million"},{"label":"EPS","value":"$3.65"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cd29f84b967c56a049116b4d7d937e19b1b34de1","claim":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported Full Year 2022 results: revenue $3.98 Billion, EPS $9.48.","evidence_excerpt":"Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance – Fourth-Quarter Revenue of $1.10 Billion and Full-Year Revenue of $3.98 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.65 and Non-GAAP Earnings per Share of $2.98 – – Full-Year GAAP Earnings per Share of $9.48 and Non-GAAP Earnings per Share of $11.12 – – Provides 2023 Guidance –","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323000326/0001157523-23-000326-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2022"},{"label":"Revenue","value":"$3.98 Billion"},{"label":"EPS","value":"$9.48"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}